Mohr E, Carter C, Wallin A
Medical Neurology Branch, NINDS, National Institutes of Health, Bethesda, MD.
Pharmacopsychiatry. 1990 Feb;23 Suppl 2:53-5. doi: 10.1055/s-2007-1014533.
Further development of clinical models of dementia to augment present unsatisfactory animal models, is of central importance to the understanding of the neurochemistry of dementia. Furthermore, present definitions of the neurotoxic processes underlying dementing disorders will need to be improved. Routine clinical markers will be necessary for the development of any therapy beyond present attempts for symptomatic treatment with neurotransmitter replacement.
进一步发展痴呆症的临床模型以补充目前不尽人意的动物模型，对于理解痴呆症的神经化学至关重要。此外，目前对导致痴呆症的神经毒性过程的定义需要改进。对于任何超出目前用神经递质替代进行对症治疗尝试的疗法的开发，常规临床标志物将是必要的。
